New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex')
1998

New Developments in Cancer Treatment with Raltitrexed

Sample size: 427 publication Evidence: moderate

Author Information

Author(s): G Blackledge

Primary Institution: Zeneca Pharmaceuticals

Hypothesis

Can raltitrexed be effectively used in combination with other agents for cancer treatment?

Conclusion

Raltitrexed shows promising efficacy and tolerability in treating advanced colorectal cancer and is being evaluated in combination therapies for various cancers.

Supporting Evidence

  • Raltitrexed has shown good tolerability and acceptability in combination therapies.
  • Preliminary results indicate raltitrexed's efficacy in cancers other than colorectal.
  • Combination therapies with raltitrexed and other agents are currently under investigation.

Takeaway

Raltitrexed is a new cancer drug that helps treat advanced colorectal cancer and is being tested with other medicines to see if it works even better.

Methodology

The study involved phase III clinical trials comparing raltitrexed with standard 5-FU-based regimens in patients with advanced colorectal cancer.

Potential Biases

Potential bias in reporting preliminary results and efficacy in combination therapies.

Limitations

The study primarily focuses on advanced colorectal cancer, limiting generalizability to other cancer types.

Participant Demographics

Patients with advanced colorectal cancer, including various demographics across multiple trials.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication